Clinical issues and research in respiratory failure from severe acute respiratory syndrome (Q45174339)

10 December 2017

Clinical issues and research in respiratory failure from severe acute respiratory syndrome (English)

1 reference

National Heart, Lung, and Blood Institute

10 December 2017

1 reference

17

object named as

National Heart, Lung, and Blood Institute

1 reference

Centers for Disease Control and Prevention

10 December 2017

18

object named as

Centers for Disease Control and Prevention

1 reference

10 December 2017

6

Frederick G Hayden

1 reference

10 December 2017

12

Arthur S Slutsky

1 reference

10 December 2017

3

Gordon R Bernard

1 reference

10 December 2017

Mitchell M Levy

1

1 reference

10 December 2017

Melisse S Baylor

2

1 reference

10 December 2017

Rob Fowler

4

1 reference

10 December 2017

Teri J Franks

5

1 reference

10 December 2017

Rita Helfand

7

1 reference

10 December 2017

Stephen E Lapinsky

8

1 reference

10 December 2017

Thomas R Martin

9

1 reference

10 December 2017

Michael S Niederman

10

1 reference

10 December 2017

Gordon D Rubenfeld

11

1 reference

10 December 2017

Thomas E Stewart

13

1 reference

10 December 2017

Barbara A Styrt

14

1 reference

10 December 2017

B Taylor Thompson

15

1 reference

10 December 2017

Andrea L Harabin

16

1 reference

10 December 2017

Institute of Allergy and Infectious Diseases

19

1 reference

10 December 2017

language of work or name

English

0 references

publication date

10 December 2004

1 reference

American Journal of Respiratory and Critical Care Medicine

10 December 2017

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

10 December 2017

171

1 reference

10 December 2017

5

1 reference

10 December 2017

518-526

1 reference

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

10 December 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Laboratory-Acquired Severe Acute Respiratory Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Critically ill patients with severe acute respiratory syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Infants born to mothers with severe acute respiratory syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Combining clinical and epidemiologic features for early recognition of SARS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Identification of severe acute respiratory syndrome in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

A major outbreak of severe acute respiratory syndrome in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Inhibition of SARS-associated coronavirus infection and replication by RNA interference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Interferon-beta 1a and SARS coronavirus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Severe acute respiratory syndrome-associated coronavirus in lung tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Synergistic antiviral effect of a combination of mouse interferon-alpha and interferon-gamma on mouse hepatitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Quality of care, process, and outcomes in elderly patients with pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Transmission of severe acute respiratory syndrome during intubation and mechanical ventilation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Glucocorticoids and acute lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

One-year outcomes in survivors of the acute respiratory distress syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Paresis acquired in the intensive care unit: a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

A novel coronavirus associated with severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Severe acute respiratory syndrome: radiographic evaluation and clinical outcome measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Our strategies for fighting severe acute respiratory syndrome (SARS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Managing SARS amidst uncertainty

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Corticosteroids: the "terminator" of all untreatable serious pulmonary illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Sucralfate suspension versus titrated antacid for the prevention of acute stress-related gastrointestinal hemorrhage in critically ill patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Neuromuscular disorder in intensive care unit patients treated with pancuronium bromide. Occurrence in a cluster group of seven patients and two sporadic cases, with electrophysiologic and histologic examination

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

ICU management of severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

Communication in the Toronto critical care community: important lessons learned during SARS

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-621WS

10.1164/RCCM.200405-621WS

21 January 2018

Identifiers

DOI

1 reference

10 December 2017

1 reference